A number of new treatment options for different stages of bladder cancer are currently under investigation, which will make education important to cover the data behind these therapies and how they might be incorporated into future clinical practice. Of interest, treatment options for bacillus Calmette Guérin (BCG)-unresponsive non–muscle invasive bladder cancer are currently being evaluated in clinical trials as well as new systemic therapy options for muscle-invasive and metastatic disease.